Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?. Aspergillose cérébrale : une infection opportuniste émergente chez les patients traités par ibrutinib pour leucémie lymphoïde chronique ?

Archive ouverte

Gaye, E | Le Bot, Audrey | Talarmin, Jean-Philippe | Le Calloch, Ronan | Belaz, Sorya | Dupont, Mathieu | Tattevin, Pierre

Edité par CCSD ; Elsevier Masson -

International audience. Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with high-risk cytogenetic abnormalities. Several cases of invasive aspergillosis have recently been reported in ibrutinib-treated patients. We report two cases of cerebral aspergillosis in CLL patients treated with ibrutinib.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion